Abstract
20 patients with poor prognosis malignant lymphoma (Hodgkin's disease 8, high grade non-Hodgkin's lymphoma 12) were treated with high-dose cyclophosphamide (120 mg/kg), etoposide (2100 mg/m2) and BCNU (400mg/m2) followed by reinfusion of autologous non-frozen bone marrow, which had been stored for 72 hours at 4°C. All evaluable patients (19/20) had a full haematopoietic reconstitution. Median time to achieve neutrophils > 500 μl was 26 days (range 15–39) and median time to achieve an unsupported platelet count >20000/μl was 29 days (range 12–55). During a median follow-up of 10.5 months (range 2–36) 2 of 8 patients with Hodgkin's disease and 3/12 patients with non-Hodgkin's lymphoma relapsed after a median of 4.5 months (range 1–6). The projected event-free survival at 24 months was 61% and 70% for patients with non-Hodgkin's lymphoma and Hodgkin's disease respectively. We conclude that high-dose chemotherapy with non-frozen autologous bone marrow transplantation is safe in terms of haematopoietic reconst...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
